Fresenius Medical Care Faces FTC Probe and Sells Latin American Clinics Amidst Labor Strikes

The latest update is out from Fresenius Medical Care ( (FMS) ).

Fresenius Medical Care AG is facing scrutiny from the U.S. Federal Trade Commission over allegations of anti-competitive practices alongside its competitor DaVita, potentially impacting its market operations. Additionally, the company has engaged in significant restructuring, including the sale of 154 dialysis clinics in Latin America to DaVita, as part of a cost-cutting program, while also dealing with labor disputes in California related to union busting accusations.

The most recent analyst rating on (FMS) stock is a Hold with a $24.00 price target. To see the full list of analyst forecasts on Fresenius Medical Care stock, see the FMS Stock Forecast page.

Spark’s Take on FMS Stock

According to Spark, TipRanks’ AI Analyst, FMS is a Outperform.

Fresenius Medical Care demonstrates solid financial performance with consistent revenue and strong cash flow. Positive momentum is evident in technical indicators, although valuation metrics suggest potential overvaluation. The company’s strategic initiatives and earnings call guidance support a positive outlook for the year.

To see Spark’s full report on FMS stock, click here.

More about Fresenius Medical Care

Fresenius Medical Care AG is a leading provider in the healthcare industry, specializing in dialysis services and products. The company operates a network of clinics and offers services primarily focused on patients with chronic kidney failure, a condition often necessitating regular dialysis treatments.

Average Trading Volume: 400,176

Technical Sentiment Signal: Buy

Current Market Cap: $16.68B

For detailed information about FMS stock, go to TipRanks’ Stock Analysis page.